1. Decreased expression of SLC39A14 is associated with tumor aggressiveness and biochemical recurrence of human prostate cancer
- Author
-
Xu XM, Wang CG, Zhu YD, Chen WH, Shao SL, Jiang FN, and Liao QD
- Subjects
tumor suppressor ,Solute carrier family 39 member 14 ,prostate cancer ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,biochemical recurrence-free survival ,lcsh:RC254-282 - Abstract
Xiao-Ming Xu,1,2 Cheng-Gong Wang,1 Yu-Di Zhu,2 Wei-Hua Chen,3 Si-Liang Shao,2 Fu-Neng Jiang,4 Qian-De Liao1 1Xiangya Hospital, Central South University, Changsha, Hunan, 2Department of Urology, Ningbo No 2 Hospital, NingboUniversity School of Medicine, Ningbo, Zhejiang, 3Shanghai East Hospital, Tongji University, Shanghai, 4Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, People’s Republic of China Objective: Solute carrier family 39, member 14 (SLC39A14), has been identified as a potential biomarker for various cancers. However, its roles in prostate cancer (PCa) are still unclear. The aim of this study was to investigate the clinical significance of SLC39A14 in patients with PCa and its functions in malignant phenotypes of PCa cells.Patients and methods: Subcellular localization and expression pattern of SLC39A14 protein were examined by immunohistochemistry. Then, the associations of SLC39A14 expression with various clinicopathological features and clinical outcome of patients with PCa were statistically evaluated. Subsequently, the effects of SLC39A14 overexpression and knockdown on PCa cell proliferation and motility were, respectively, examined by Cell Counting Kit-8, transwell, and wound-healing assays.Results: The immunoreactive scores of SLC39A14 protein in human PCa tissues were significantly lower than those in normal prostate tissues. Based on the Taylor dataset, SLC39A14 downregulation occurred more frequently in patients with PCa with a higher Gleason score (P
- Published
- 2016